ALAlphabet Inc.
Institutional investor · Portfolio as of Q2 2023
Top Holdings47 positions
UIPATH INC CL A | 14.1M | $233.1M | 12.5% | $12.71 | +31.08% | 3 qtrssince 2022-Q4 | Unchanged 0 |
VERVE THERAPEUTICS INC | 10.5M | $197.8M | 10.6% | — | — | 3 qtrssince 2022-Q4 | Unchanged 0 |
OSCAR HEALTH INC CL A | 24M | $193.8M | 10.4% | $2.46 | +234.15% | 3 qtrssince 2022-Q4 | Unchanged 0 |
Crowdstrike Holdings Inc | 1.3M | $188.5M | 10.1% | $120.06 | +19.93% | 3 qtrssince 2022-Q4 | Increased 66 |
PRIME MEDICINE INC | 11.9M | $173.8M | 9.3% | $18.58 | -20.08% | 3 qtrssince 2022-Q4 | Decreased 0 |
DEXCOM INC | 1.2M | $155.9M | 8.4% | $113.24 | +12.98% | 3 qtrssince 2022-Q4 | Decreased 0 |
GITLAB INC CLASS A COM | 2.6M | $135.3M | 7.3% | $43.53 | +13.71% | 3 qtrssince 2022-Q4 | Increased 78 |
PLANET LABS PBC COM CL A | 31.9M | $102.9M | 5.5% | $4.35 | -29.20% | 3 qtrssince 2022-Q4 | Unchanged 0 |
Snowflake Inc | 535,604 | $94.3M | 5.1% | $143.54 | +22.45% | 3 qtrssince 2022-Q4 | Unchanged 0 |
EQRx Inc. | 47.7M | $88.7M | 4.8% | — | — | 3 qtrssince 2022-Q4 | Unchanged 0 |
FRESHWORKS INC CLASS A COM | 4M | $70.9M | 3.8% | $14.71 | +19.65% | 3 qtrssince 2022-Q4 | Unchanged 0 |
LYFT INC | 3.7M | $35.5M | 1.9% | $11.02 | +47.19% | 3 qtrssince 2022-Q4 | Unchanged 0 |
Benson Hill Inc. | 15.4M | $20M | 1.1% | — | — | 3 qtrssince 2022-Q4 | Unchanged 0 |
Relay Therapeutics Inc | 1.6M | $19.7M | 1.1% | $14.94 | -14.32% | 3 qtrssince 2022-Q4 | Unchanged 0 |
Desktop Metal Inc. | 11M | $19.6M | 1.1% | — | — | — | Unchanged 0 |
LYELL IMMUNOPHARMA INC | 5.9M | $18.7M | 1.0% | — | — | — | Unchanged 0 |
SANA BIOTECHNOLOGY INC COM | 2.8M | $16.8M | 0.9% | $3.95 | +49.37% | 3 qtrssince 2022-Q4 | Unchanged 0 |
BEAM THERAPEUTICS INC COM | 321,604 | $10.3M | 0.6% | $39.11 | -18.67% | 3 qtrssince 2022-Q4 | Unchanged 0 |
RAPT Therapeutics Inc. | 540,270 | $10.1M | 0.5% | — | — | — | Unchanged 0 |
MONTE ROSA THERAPEUTICS INC COM | 1.5M | $10M | 0.5% | $7.61 | -11.43% | 3 qtrssince 2022-Q4 | Unchanged 0 |
Alphabet Inc. manages $1.9B across 47 positions as of Q2 2023. Top holdings: PATH (12.5%), VERV (10.6%), OSCR (10.4%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2.5/5.0.
Added 1 new position, exited 3, increased 2, trimmed 3. Top move: GTLB (INCREASED, conviction 78). Portfolio: $1.9B across 47 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR